Switch theme
Sign up to access all valuation multiples
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
1987
23.8K+
LTM Revenue $8.3B
LTM EBITDA $2.0B
$16.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Grifols has a last 12-month revenue (LTM) of $8.3B and a last 12-month EBITDA of $2.0B.
In the most recent fiscal year, Grifols achieved revenue of $8.1B and an EBITDA of $1.7B.
Grifols expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Grifols valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.3B | XXX | $8.1B | XXX | XXX | XXX |
| Gross Profit | $3.3B | XXX | $3.1B | XXX | XXX | XXX |
| Gross Margin | 39% | XXX | 39% | XXX | XXX | XXX |
| EBITDA | $2.0B | XXX | $1.7B | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 21% | XXX | XXX | XXX |
| EBIT | $1.5B | XXX | $1.3B | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $310M | XXX | $176M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $8.9B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Grifols's stock price is EUR 9 (or $10).
Grifols has current market cap of EUR 5.9B (or $6.6B), and EV of EUR 15.0B (or $16.8B).
See Grifols trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16.8B | $6.6B | XXX | XXX | XXX | XXX | $0.78 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Grifols has market cap of $6.6B and EV of $16.8B.
Grifols's trades at 2.1x EV/Revenue multiple, and 10.1x EV/EBITDA.
Equity research analysts estimate Grifols's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Grifols has a P/E ratio of 21.3x.
See valuation multiples for Grifols and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.6B | XXX | $6.6B | XXX | XXX | XXX |
| EV (current) | $16.8B | XXX | $16.8B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 8.2x | XXX | 10.1x | XXX | XXX | XXX |
| EV/EBIT | 11.6x | XXX | 13.0x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.3x | XXX | 37.5x | XXX | XXX | XXX |
| EV/FCF | 40.0x | XXX | 28.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGrifols's last 12 month revenue growth is 6%
Grifols's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Grifols's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Grifols's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Grifols and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 26% | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Grifols acquired XXX companies to date.
Last acquisition by Grifols was XXXXXXXX, XXXXX XXXXX XXXXXX . Grifols acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Grifols founded? | Grifols was founded in 1987. |
| Where is Grifols headquartered? | Grifols is headquartered in Spain. |
| How many employees does Grifols have? | As of today, Grifols has 23.8K+ employees. |
| Who is the CEO of Grifols? | Grifols's CEO is Mr. Jose Ignacio Abia Buenache. |
| Is Grifols publicy listed? | Yes, Grifols is a public company listed on MAD. |
| What is the stock symbol of Grifols? | Grifols trades under GRF ticker. |
| When did Grifols go public? | Grifols went public in 2006. |
| Who are competitors of Grifols? | Similar companies to Grifols include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Grifols? | Grifols's current market cap is $6.6B |
| What is the current revenue of Grifols? | Grifols's last 12 months revenue is $8.3B. |
| What is the current revenue growth of Grifols? | Grifols revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Grifols? | Current revenue multiple of Grifols is 2.0x. |
| Is Grifols profitable? | Yes, Grifols is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Grifols? | Grifols's last 12 months EBITDA is $2.0B. |
| What is Grifols's EBITDA margin? | Grifols's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Grifols? | Current EBITDA multiple of Grifols is 8.2x. |
| What is the current FCF of Grifols? | Grifols's last 12 months FCF is $420M. |
| What is Grifols's FCF margin? | Grifols's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Grifols? | Current FCF multiple of Grifols is 40.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
